AMEDISYS INC (AMED)

US0234361089 - Common Stock

92.46  +0.17 (+0.18%)

After market: 92.46 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AMED. AMED was compared to 116 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of AMED get a neutral evaluation. Nothing too spectacular is happening here. AMED does not seem to be growing, but still is valued expensively.



5

1. Profitability

1.1 Basic Checks

In the past year AMED was profitable.
AMED had a positive operating cash flow in the past year.
AMED had positive earnings in 4 of the past 5 years.
AMED had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

AMED has a Return On Assets of -0.47%. This is comparable to the rest of the industry: AMED outperforms 55.17% of its industry peers.
AMED's Return On Equity of -0.92% is in line compared to the rest of the industry. AMED outperforms 57.76% of its industry peers.
AMED has a Return On Invested Capital of 8.61%. This is amongst the best in the industry. AMED outperforms 83.62% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMED is above the industry average of 8.65%.
Industry RankSector Rank
ROA -0.47%
ROE -0.92%
ROIC 8.61%
ROA(3y)5.6%
ROA(5y)7.71%
ROE(3y)10.94%
ROE(5y)15.06%
ROIC(3y)11.18%
ROIC(5y)12.42%

1.3 Margins

AMED has a better Operating Margin (7.73%) than 79.31% of its industry peers.
In the last couple of years the Operating Margin of AMED has declined.
With a decent Gross Margin value of 44.31%, AMED is doing good in the industry, outperforming 73.28% of the companies in the same industry.
In the last couple of years the Gross Margin of AMED has grown nicely.
Industry RankSector Rank
OM 7.73%
PM (TTM) N/A
GM 44.31%
OM growth 3Y-1.84%
OM growth 5Y-1.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.18%
GM growth 5Y1.92%

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMED is creating some value.
Compared to 1 year ago, AMED has more shares outstanding
The number of shares outstanding for AMED has been increased compared to 5 years ago.
Compared to 1 year ago, AMED has an improved debt to assets ratio.

2.2 Solvency

AMED has an Altman-Z score of 3.71. This indicates that AMED is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AMED (3.71) is better than 79.31% of its industry peers.
The Debt to FCF ratio of AMED is 3.20, which is a good value as it means it would take AMED, 3.20 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AMED (3.20) is better than 79.31% of its industry peers.
AMED has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AMED (0.34) is better than 66.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.2
Altman-Z 3.71
ROIC/WACC1.01
WACC8.49%

2.3 Liquidity

AMED has a Current Ratio of 1.05. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.05, AMED is doing worse than 69.83% of the companies in the same industry.
A Quick Ratio of 1.05 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a Quick ratio of 1.05. This is in the lower half of the industry: AMED underperforms 60.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.05

2

3. Growth

3.1 Past

AMED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.37%.
The Earnings Per Share has been growing slightly by 3.28% on average over the past years.
AMED shows a small growth in Revenue. In the last year, the Revenue has grown by 0.59%.
The Revenue has been growing slightly by 6.11% on average over the past years.
EPS 1Y (TTM)-14.37%
EPS 3Y-11.17%
EPS 5Y3.28%
EPS growth Q2Q-18.97%
Revenue 1Y (TTM)0.59%
Revenue growth 3Y2.59%
Revenue growth 5Y6.11%
Revenue growth Q2Q1.55%

3.2 Future

AMED is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.25% yearly.
AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.78% yearly.
EPS Next Y8.29%
EPS Next 2Y9.96%
EPS Next 3Y-1.25%
EPS Next 5YN/A
Revenue Next Year3.99%
Revenue Next 2Y5.36%
Revenue Next 3Y4.78%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

3

4. Valuation

4.1 Price/Earnings Ratio

AMED is valuated rather expensively with a Price/Earnings ratio of 21.55.
72.41% of the companies in the same industry are more expensive than AMED, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.42. AMED is around the same levels.
The Price/Forward Earnings ratio is 19.90, which indicates a rather expensive current valuation of AMED.
Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than the industry average as 69.83% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.74, AMED is valued at the same level.
Industry RankSector Rank
PE 21.55
Fwd PE 19.9

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as AMED.
Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than 63.79% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.27
EV/EBITDA 16.73

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMED does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.6
PEG (5Y)6.56
EPS Next 2Y9.96%
EPS Next 3Y-1.25%

0

5. Dividend

5.1 Amount

AMED does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

AMEDISYS INC

NASDAQ:AMED (3/27/2024, 8:00:00 PM)

After market: 92.46 0 (0%)

92.46

+0.17 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.02B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 21.55
Fwd PE 19.9
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.6
PEG (5Y)6.56
Profitability
Industry RankSector Rank
ROA -0.47%
ROE -0.92%
ROCE
ROIC
ROICexc
ROICexgc
OM 7.73%
PM (TTM) N/A
GM 44.31%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.09
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.05
Quick Ratio 1.05
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-14.37%
EPS 3Y-11.17%
EPS 5Y
EPS growth Q2Q
EPS Next Y8.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0.59%
Revenue growth 3Y2.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y